<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753606</url>
  </required_header>
  <id_info>
    <org_study_id>TA-8995-201</org_study_id>
    <nct_id>NCT04753606</nct_id>
  </id_info>
  <brief_title>Randomized Study of Obicetrapib as an Adjunct to Statin Therapy</brief_title>
  <acronym>ROSE</acronym>
  <official_title>A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewAmsterdam Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NewAmsterdam Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study&#xD;
      to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to&#xD;
      high-intensity statin therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study&#xD;
      to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to&#xD;
      high-intensity statin therapy. The screening period for this study will take up to 2-weeks.&#xD;
      Afterwards patients will be randomized to placebo, 5 mg obicetrapib or 10 mg obicetrapib for&#xD;
      an 8-week treatment period. After the treatment period, patients will continue for a 4-week&#xD;
      safety follow-up and a 15-week PK follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled, double-blind, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo tablet made to resemble active</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>8-weeks</time_frame>
    <description>Percent change in LDL-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ApoB</measure>
    <time_frame>8-weeks</time_frame>
    <description>Percent change in ApoB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-HDL-C</measure>
    <time_frame>8-weeks</time_frame>
    <description>Percent change in Non-HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C</measure>
    <time_frame>8-weeks</time_frame>
    <description>Percent change in HDL-C</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>High Cholesterol</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once-daily placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obicetrapib 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once-daily obicetrapib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obicetrapib 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once-daily obicetrapib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obicetrapib</intervention_name>
    <description>tablets</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>obicetrapib 10 mg</arm_group_label>
    <arm_group_label>obicetrapib 5 mg</arm_group_label>
    <other_name>CETP inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  LDL-C &gt; 70 mg/dL and TG &lt; 400 mg/dL,&#xD;
&#xD;
          -  Treated with a high-intensity statin therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 40 kg/m&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  HbA1c &gt; 10%&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Active muscle disease&#xD;
&#xD;
          -  GFR &lt; 60 ml/min&#xD;
&#xD;
          -  Hepatic dysfunction&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Treatment with investigational product&#xD;
&#xD;
          -  Treatment with PCSK9&#xD;
&#xD;
          -  Clinically significant condition&#xD;
&#xD;
          -  Known CETP inhibitor allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Cardiovascular Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Healthcare Research LLC</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakland Medical Research Center</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Endocrinology Consultants, P.C.</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research, LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Group, LLC</name>
      <address>
        <city>Munroe Falls</city>
        <state>Ohio</state>
        <zip>44262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monument Health Clinical Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LL</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obicetrapib</keyword>
  <keyword>statin</keyword>
  <keyword>LDL-C</keyword>
  <keyword>cholesterol</keyword>
  <keyword>atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

